CIK 0000886163 · Large accelerated filer
LIGAND PHARMACEUTICALS INC
Sign in to watch- Tickers
- LGND LGNDZ LGNXZ LGNYZ LGNZZ
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 770160744
- Phone
- 858-550-7500
- Business address
- 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO, CA, 92121
- Former names
- LIGAND PHARMACEUTICALS
Securities
- LGND Common Stock Nasdaq
- LGNDZ Common stock OTC
- LGNXZ Common stock OTC
- LGNYZ Common stock OTC
- LGNZZ Common stock OTC
- 8-K Event Executive or director change · Regulation FD disclosure
- 3 Insider Initial Statement of Ownership
- 4/A Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 8-K Event Other events
- 8-K Event Other events
- 4 Option exercise President and COO acquired 1,005 shares (option exercise)
- 4 Open-market buy Director bought 750 shares at $87.01 ($65,258)
- 4 Open-market buy EVP,Finance & Strategy and CFO bought 500 shares at $86.18 ($43,091)
- 4 Option exercise President and COO acquired 1,163 shares (option exercise)
- S-8 Other Securities Offered to Employees in Benefit Plans
- 10-Q Report Quarterly Report
- 4 Open-market buy Director bought 746 shares at $90.01 ($67,146)
- 4 Option exercise SVP, Gen. Counsel & Secretary acquired 1,093 shares (option exercise)
- 4 Open-market buy Director bought 1,000 shares at $93.59 ($93,594)
- 4 Shares withheld for taxes Director gave up 847 shares (to pay taxes)
- 4 Open-market buy Director bought 1,000 shares at $95.98 ($95,980)
- 4 Open-market sale Director sold 4,091 shares at $94.45 ($386,395)
- 4 Open-market buy Chief Executive Officer bought 1,850 shares at $95.45 ($176,583)
Page 32 of 115 · 2,300 filings